Holen Sie sich die Stockscreener-App
27.73
2.78%
0.75
Handel nachbörslich:
27.90
0.17
+0.61%
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Perceptive-linked holders report 3.97M shares of Zymeworks (ZYME) - Stock Titan
Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline strategy is suddenly worth a closer l - AD HOC NEWS
Zymeworks (ZYME) price target increased by 12.53% to 40.88 - MSN
Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript - MSN
How Investors Are Reacting To Zymeworks (ZYME) Elevating EcoR1 Veterans To Key Executive Roles - simplywall.st
Zymeworks Inc stock (US98986T1088): Why its biopharma pipeline is suddenly worth a closer look - AD HOC NEWS
HC Wainwright & Co. Upgrades Zymeworks (ZYME) - MSN
JPMorgan Chase & Co. Cuts Stock Position in Zymeworks Inc. $ZYME - MarketBeat
ZYME SEC FilingsZymeworks 10-K, 10-Q, 8-K Forms - Stock Titan
Zymeworks (NASDAQ: ZYME) awards options, RSUs and PSUs to officer - Stock Titan
Zymeworks (NASDAQ: ZYME) awards options, RSUs and PSUs to EVP - Stock Titan
Zymeworks (ZYME) executive reports significant option and RSU awards - Stock Titan
Zymeworks (ZYME) EVP holds 167,000 options and 111,111 RSUs - Stock Titan
Zymeworks names Schayowitz as R&D head, Platshon as CBO By Investing.com - Investing.com Australia
Investment Recap: Should I average down on Zymeworks Inc stock2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn
Zymeworks Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth - wahanariau.com
Zymeworks Bolsters Executive Team to Drive Next Phase of Growth - TipRanks
Zymeworks names Schayowitz as R&D head, Platshon as CBO - Investing.com
Zymeworks Inc. Appoints Adam Schayowitz as Head of R&D and Scott Platshon as Chief Business Officer, Effective April 9, 2026 - marketscreener.com
Buybacks Report: Will Zymeworks Inc benefit from geopolitical trends2026 Intraday Action & Weekly Sector Rotation Insights - baoquankhu1.vn
Why Zymeworks (ZYME) Is Up 6.7% After FDA Fast Track Win And CFO Appointment - Sahm
Zymeworks (NASDAQ: ZYME) grants CFO large option and RSU awards - Stock Titan
Zymeworks (NASDAQ: ZYME) CFO reports zero beneficial share ownership - Stock Titan
Short Squeeze: Will Zymeworks Inc benefit from rising consumer demand2026 Macro Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME - MarketBeat
A Look At Zymeworks (ZYME) Valuation After Fast Track Win And New CFO Appointment - Sahm
ZYME PE Ratio & Valuation, Is ZYME Overvalued - Intellectia AI
ZYME Technical Analysis & Stock Price Forecast - Intellectia AI
Zymeworks Inc. R (ZA8.DU) Q1 FY2025 earnings call transcript - Yahoo Finance
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Q3 2025 Zymeworks Inc Earnings Call Transcript - GuruFocus
Trade Report: How sensitive is Zymeworks Inc to inflationMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
ZymeworksLeveraging Partnerships For Value - RTTNews
Zymeworks appoints Kristin Stafford as chief financial officer By Investing.com - Investing.com South Africa
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance Singapore
Trade Recap: Can Zymeworks Inc grow without dilution2026 Movers & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Zymeworks appoints Kristin Stafford as CFO - MSN
Zymeworks Inc. Announces Executive Changes, Effective from April 1, 2026 - marketscreener.com
Zymeworks Appoints Kristin Stafford as Chief Financial Officer - wahanariau.com
Zymeworks Names Kristin Stafford as New Chief Financial Officer - TipRanks
Zymeworks Appoints Kristin Stafford as Chief Financial Officer to Drive Strategic Growth and Value Creation - Minichart
Zymeworks appoints Kristin Stafford as chief financial officer - Investing.com
Kristin Stafford named Zymeworks executive VP and CFO as Kenneth Galbraith steps down as interim CFO - TradingView
Kristin Stafford joins Zymeworks (Nasdaq: ZYME) as new Chief Financial Officer - Stock Titan
How Investors May Respond To Zymeworks (ZYME) Fast Track Nod For Ovarian Cancer ADC ZW191 - Yahoo Finance
FDA grants fast track status to Zymeworks’ ZW191 for ovarian cancer By Investing.com - Investing.com South Africa
FDA grants fast track status to Zymeworks’ ZW191 for ovarian cancer - Investing.com Australia
Systematic Evaluation of Maleimide Spacer Impact on Drug-Linker Deconjugation in Antibody-Drug Conjugates Ex Vivo and In Vivo - ACS Publications
Investment Report: Will Zymeworks Inc benefit from geopolitical trendsPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
Zymeworks Inc Receives U S Fda Fast Track Designation for Zw191 an Fra Targeting Antibody Drug Conjugate - marketscreener.com
Zymeworks Wins FDA Fast Track Status for Ovarian Cancer Drug ZW191 - TipRanks
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):